Viveve Medical Stock Forecast, Price & News

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

Is Viveve Medical a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Viveve Medical stock.
View analyst ratings for Viveve Medical or view top-rated stocks.

How has Viveve Medical's stock been impacted by Coronavirus (COVID-19)?

Viveve Medical's stock was trading at $0.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VIVE stock has increased by 65.5% and is now trading at $1.39.
View which stocks have been most impacted by COVID-19.

Are investors shorting Viveve Medical?

Viveve Medical saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 404,000 shares, a drop of 32.9% from the October 14th total of 601,800 shares. Based on an average daily volume of 471,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 4.0% of the company's shares are short sold.
View Viveve Medical's Short Interest.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Viveve Medical.

How were Viveve Medical's earnings last quarter?

Viveve Medical, Inc. (NASDAQ:VIVE) posted its quarterly earnings data on Thursday, November, 11th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.09. Viveve Medical had a negative trailing twelve-month return on equity of 108.23% and a negative net margin of 323.58%. During the same quarter last year, the company posted ($2.60) EPS.
View Viveve Medical's earnings history.

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the following people:

• Scott C. Durbin, Chief Executive Officer & Director
• Marty Kerber, Vice President-Research, Development & Operations
• Jim B. Robbins, CFO, Chief Accounting Officer & Senior VP-Finance
• Doug Massey, Vice President-Clinical & Medical Affairs
• Jeff Sinclair, Vice President-International Sales

Who are some of Viveve Medical's key competitors?

Some companies that are related to Viveve Medical include electroCore (ECOR), Soleno Therapeutics (SLNO), Yubo International Biotech (YBGJ), Fc Global Realty (FCRE), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), Helius Medical Technologies (HSDT), Positron (POSC), Nuwellis (NUWE), Star Equity (STRR), Micron Solutions (MICR), Guided Therapeutics (GTHP), Vaso (VASO), ADM Tronics Unlimited (ADMT) and ReShape Lifesciences (RSLSD).
View all of VIVE's competitors.

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX).

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.49%), Morgan Stanley (0.23%) and Dimensional Fund Advisors LP (0.16%).
View institutional ownership trends for Viveve Medical.

Which major investors are buying Viveve Medical stock?

VIVE stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Dimensional Fund Advisors LP, and Geode Capital Management LLC.
View insider buying and selling activity for Viveve Medical or or view top insider-buying stocks.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $1.39.

How much money does Viveve Medical make?

Viveve Medical has a market capitalization of $14.72 million and generates $5.48 million in revenue each year.

How many employees does Viveve Medical have?

Viveve Medical employs 2,018 workers across the globe.

What is Viveve Medical's official website?

The official website for Viveve Medical is www.viveve.com.

Where are Viveve Medical's headquarters?

Viveve Medical is headquartered at 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at (720) 696-8100, via email at [email protected], or via fax at 720-696-8199.